Atopic dermatitis: real-life experience with tralokinumab after dupilumab failure: a case series
-
Published:2024-09
Issue:5
Volume:99
Page:721-724
-
ISSN:0365-0596
-
Container-title:Anais Brasileiros de Dermatologia
-
language:en
-
Short-container-title:Anais Brasileiros de Dermatologia
Author:
Amoedo PatríciaORCID,
Rosa GilbertoORCID,
Baudrier TeresaORCID,
Pedrosa Ana FilipaORCID,
Cruz Maria JoãoORCID
Reference10 articles.
1. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2);Wollenberg;Br J Dermatol,2021
2. Tralokinumab in the treatment of resistant atopic dermatitis: an open-label, retrospective case series study;Pezzolo;J Eur Acad Dermatol Venereol,2023
3. The evolving landscape of biologic therapies for atopic dermatitis: present and future perspective;David;Clin Exp Allergy,2023
4. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis;Silverberg;Am J Clin Dermatol,2022
5. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis;Bieber;Allergy,2020